Follow Us

       


"Like" us on Facebook

Clinical Trials

Disease or Condition
Cancer - Non-Hodgkin Lymphoma
Title
Previously treated Indolent NHL
Description
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101 ) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Non-Hodgkin Lymphoma - GS-US-313-0125/Gilead
IRB Number
NCT01732926
Treatment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101 ) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Inclusion/Notes

For more information, please click here: http://www.clinicaltrials.gov/ct2/show/NCT01732926?term=NCT01732926&rank=1

Status
Open to Enrollment
Principal Investigator
Daniel R Greenwald, MD
Contact Email
research@ccsb.org
Phone
(805) 898-2117

This is the fat footer - edit page 906 to add content.